
Shire Announces Results for Phase II/III Clinical Trial in Children with Hunter Syndrome and Cognitive Impairment
Shire, Rani Therapeutics to Evaluate Use of Rani Pill Technology for Oral Delivery of Factor Therapy
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654
Shire, Shinogi Report Positive Phase III Results for Adult ADHD Treatment
Shire Gains Fast Track Designation for SHP607 for Prevention of Chronic Lung Disease in Extremely Premature Infants
Shire’s Chronic Lung Disease Prevention Treatment for Preemies Receives FDA Fast Track
Shire receives FDA Fast Track designation for SHP607 for the prevention of chronic lung disease in extremely premature infants. Shire plc announced that the U.S. FDA has granted Fast Track designation for SHP607 for the prevention of chronic lung disease in extremely premature infants. SHP607, currently in phase 2 clinical development, is a recombinant human version…